GB8817743D0
(en)
|
1988-07-26 |
1988-09-01 |
Fujisawa Pharmaceutical Co |
Fr901228 substance & preparation thereof
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5545522A
(en)
|
1989-09-22 |
1996-08-13 |
Van Gelder; Russell N. |
Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
|
JPH0764872A
(ja)
|
1993-08-26 |
1995-03-10 |
Fujitsu Ten Ltd |
データ記憶制御装置
|
US5578832A
(en)
|
1994-09-02 |
1996-11-26 |
Affymetrix, Inc. |
Method and apparatus for imaging a sample on a device
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5556752A
(en)
|
1994-10-24 |
1996-09-17 |
Affymetrix, Inc. |
Surface-bound, unimolecular, double-stranded DNA
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US5776905A
(en)
|
1996-08-08 |
1998-07-07 |
The Board Of Trustees Of The Leland Stamford Junior University |
Apoptotic regression of intimal vascular lesions
|
US6030961A
(en)
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
EP1010705A4
(en)
|
1997-09-02 |
2004-09-15 |
Sumitomo Pharma |
NEW CYCLIC TETRAPEPTIDE DERIVATIVES AND THEIR MEDICAL USE
|
JPH11335375A
(ja)
|
1998-05-20 |
1999-12-07 |
Mitsui Chem Inc |
ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US20070148228A1
(en)
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
US6723338B1
(en)
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
WO2001018171A2
(en)
|
1999-09-08 |
2001-03-15 |
Sloan-Kettering Institute For Cancer Research |
Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
ES2282751T3
(es)
|
1999-12-08 |
2007-10-16 |
Cyclacel Pharmaceuticals, Inc. |
Uso de depsipeptidos y sus congeneres como inmunodepresores para tratar una enfermedad infecciosa, una enfermedad autoinmunitaria, reacciones alergicas o una enfermedad cutanea hiperproliferativa.
|
CA2317003A1
(en)
|
2000-02-28 |
2001-08-28 |
Hidenori Nakajima |
Gene expression potentiator
|
JP2001348340A
(ja)
|
2000-06-07 |
2001-12-18 |
Yamanouchi Pharmaceut Co Ltd |
ヒストン脱アセチル化酵素阻害剤
|
DE60137932D1
(de)
|
2000-07-17 |
2009-04-23 |
Astellas Pharma Inc |
Reduziertes fk228 und seine verwendung
|
AU2001285042A1
(en)
*
|
2000-08-18 |
2002-03-04 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
EP1313872A1
(en)
|
2000-09-01 |
2003-05-28 |
Fujisawa Pharmaceutical Co., Ltd. |
A method of producing fr901228
|
AU2002243231A1
(en)
|
2000-11-21 |
2002-07-24 |
Wake Forest University |
Method of treating autoimmune diseases
|
JP2005507231A
(ja)
|
2001-01-10 |
2005-03-17 |
アメリカ合衆国 |
甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤
|
EP1353693B1
(en)
*
|
2001-01-16 |
2005-03-16 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
EP1390491B1
(en)
|
2001-05-02 |
2008-07-16 |
The Regents of the University of California |
Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
|
ATE474568T1
(de)
|
2001-05-30 |
2010-08-15 |
Univ Michigan |
Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
|
US7171311B2
(en)
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
JP4238728B2
(ja)
|
2001-08-21 |
2009-03-18 |
アステラス製薬株式会社 |
ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
|
WO2003017763A1
(en)
|
2001-08-24 |
2003-03-06 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
AU2002353891A1
(en)
|
2001-10-25 |
2003-05-06 |
Buck Institute For Age Research |
Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
|
WO2003038060A2
(en)
|
2001-11-01 |
2003-05-08 |
The Regents Of The University Of Michigan |
Small molecule inhibitors targeted at bcl-2
|
WO2003053468A1
(en)
|
2001-12-21 |
2003-07-03 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
US20030134423A1
(en)
|
2002-01-04 |
2003-07-17 |
Chu Yong Liang |
Compounds for delivering substances into cells
|
JP2005525345A
(ja)
|
2002-02-15 |
2005-08-25 |
スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ |
Trx媒介性疾患を処置する方法
|
WO2003070754A1
(fr)
|
2002-02-20 |
2003-08-28 |
Minoru Yoshida |
Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
|
BR0308250A
(pt)
|
2002-03-04 |
2005-01-11 |
Aton Pharma Inc |
Métodos de indução de diferenciação terminal
|
US20040077591A1
(en)
|
2002-03-28 |
2004-04-22 |
The Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
|
MXPA04009761A
(es)
|
2002-04-05 |
2005-05-27 |
Fujisawa Pharmaceutical Co |
Dipsipeptido para terapia de cancer renal.
|
EP1501489A4
(en)
|
2002-04-15 |
2007-11-21 |
Sloan Kettering Inst Cancer |
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
US20040002447A1
(en)
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
WO2004009771A2
(en)
|
2002-07-24 |
2004-01-29 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
CA2495354A1
(en)
|
2002-08-20 |
2004-03-04 |
Yamanouchi Pharmaceutical Co., Ltd. |
An agent for inhibiting articular cartilage extracellular matrix degradation
|
US20060100140A1
(en)
|
2002-09-13 |
2006-05-11 |
Paul Dent |
Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
|
SE0300098D0
(sv)
|
2003-01-15 |
2003-01-15 |
Forskarpatent I Syd Ab |
Use of cyclin D1 inhibitors
|
US20050222013A1
(en)
|
2003-01-16 |
2005-10-06 |
Georgetown University |
Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
|
WO2004074478A1
(ja)
|
2003-02-19 |
2004-09-02 |
Astellas Pharma Inc. |
ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
|
WO2004096289A1
(ja)
|
2003-04-25 |
2004-11-11 |
Fujisawa Pharmaceutical Co |
遺伝子導入効率増強剤
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
DE602004027244D1
(de)
|
2003-06-27 |
2010-07-01 |
Astellas Pharma Inc |
Therapeutisches mittel für ein weichteilsarkom
|
NZ580384A
(en)
|
2003-07-23 |
2011-03-31 |
Bayer Pharmaceuticals Corp |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
BRPI0413826A
(pt)
|
2003-08-26 |
2006-10-24 |
Aton Pharma Inc |
processo de tratamento de cáncer com inibidores de hdac
|
EP2226072A1
(en)
|
2003-08-29 |
2010-09-08 |
Aton Pharma, Inc. |
Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
JP2007505914A
(ja)
|
2003-09-18 |
2007-03-15 |
コンビナトアールエックス インコーポレーティッド |
新生物の治療のための薬物の併用方法
|
WO2005030239A2
(en)
|
2003-09-25 |
2005-04-07 |
Astellas Pharma Inc. |
Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
|
US8614318B2
(en)
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
WO2005051430A1
(de)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
|
EP1689446B1
(de)
|
2003-11-14 |
2015-01-07 |
Per Sonne Holm |
Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
WO2005058298A2
(en)
|
2003-12-10 |
2005-06-30 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
US7951780B2
(en)
|
2004-02-25 |
2011-05-31 |
Astellas Pharma Inc. |
Antitumor agent
|
US20050187148A1
(en)
|
2004-02-25 |
2005-08-25 |
Yoshinori Naoe |
Antitumor agent
|
CA2557568C
(en)
|
2004-02-27 |
2014-05-27 |
Jane Trepel |
Pharmacodynamic assays using flow cytometry
|
GB0405349D0
(en)
|
2004-03-10 |
2004-04-21 |
Univ Birmingham |
Cancer therapy and medicaments therefor
|
ITMI20040876A1
(it)
|
2004-04-30 |
2004-07-30 |
Univ Degli Studi Milano |
Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
|
DK1591109T3
(da)
|
2004-04-30 |
2008-10-06 |
Topotarget Germany Ag |
Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
|
WO2005115149A2
(en)
|
2004-05-20 |
2005-12-08 |
Dow Agrosciences Llc |
Insectidal activity of a cyclic peptide
|
WO2005117930A2
(en)
|
2004-06-04 |
2005-12-15 |
Sloan-Kettering Institute For Cancer Research |
Use of thioredoxin measurements for diagnostics and treatments
|
US7470722B2
(en)
|
2004-06-10 |
2008-12-30 |
Kalypsys, Inc. |
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
|
US20060018921A1
(en)
|
2004-07-16 |
2006-01-26 |
Baylor College Of Medicine |
Histone deacetylase inhibitors and cognitive applications
|
US7745446B2
(en)
|
2004-09-06 |
2010-06-29 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolo[1,5-c]pyrimidines
|
EP1812036A2
(en)
|
2004-11-17 |
2007-08-01 |
The University Of Chicago |
Histone deacetylase inhibitors and methods of use
|
WO2006060382A2
(en)
|
2004-11-30 |
2006-06-08 |
Trustees Of The University Of Pennsylvania |
Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
|
WO2006060429A2
(en)
|
2004-12-03 |
2006-06-08 |
Novartis Ag |
Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
|
US20060128660A1
(en)
|
2004-12-10 |
2006-06-15 |
Wisconsin Alumni Research Foundation |
FK228 analogs and methods of making and using the same
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
EP1743654A1
(en)
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
|
US7943568B2
(en)
|
2005-09-30 |
2011-05-17 |
The Ohio State University Research Foundation |
Antitumor agents
|
TW200800354A
(en)
*
|
2005-10-28 |
2008-01-01 |
Kyowa Hakko Kogyo Kk |
Concentration crystallizer and method
|
AU2006315760A1
(en)
|
2005-11-10 |
2007-05-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Materials and methods for ABCB1 polymorphic variant screening, diagnosis, and treatment
|
CA2630216A1
(en)
|
2005-11-18 |
2007-05-31 |
Gloucester Pharmaceuticals, Inc. |
Metabolite derivatives of the hdac inhibitor fk228
|
EP2012801A4
(en)
|
2006-04-24 |
2009-08-05 |
Gloucester Pharmaceuticals Inc |
GEMCITABINE COMBINATION THERAPY
|
WO2007146730A2
(en)
|
2006-06-08 |
2007-12-21 |
Gloucester Pharmaceuticals |
Deacetylase inhibitor therapy
|
CA2654566A1
(en)
|
2006-06-09 |
2007-12-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
US7857804B2
(en)
|
2006-09-01 |
2010-12-28 |
Mccaffrey Timothy A |
Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
|
CA2674309A1
(en)
|
2006-12-29 |
2008-07-10 |
Gloucester Pharmaceuticals, Inc. |
Preparation of romidepsin
|
EP2450049A1
(en)
|
2006-12-29 |
2012-05-09 |
Gloucester Pharmaceuticals, Inc. |
Romidepsin-based treatments for cancer
|
CN102276689A
(zh)
|
2011-05-09 |
2011-12-14 |
中国药科大学 |
组蛋白去乙酰化酶抑制剂fk228的化学合成方法及其应用
|